School of Pharmacy, Chongqing Medical and Pharmaceutical College, Chongqing, China.
Department of Infectious Disease, The Fifth People's Hospital of Chongqing, Chongqing, China.
J Drug Target. 2020 Aug-Sep;28(7-8):727-731. doi: 10.1080/1061186X.2020.1769637. Epub 2020 May 26.
Emerging infectious diseases, the persistent potential for destabilising pandemics, remain a global threat leading to excessive morbidity and mortality. The current outbreak of pneumonia caused by 2019 novel coronavirus (COVID-19) illustrated difficulties in lack of effective drugs for treatment. Accurate and rapid diagnostic tools are essential for early recognition and treatment of infectious diseases, allowing timely implementation of infection control, improved clinical care and other public health measures to stop the spread of the disease. CRISPR-Cas technology speed up the development of infectious disease diagnostics with high rapid and accurate. In this review, we summarise current advance regarding diverse CRISPR-Cas systems, including CRISPR-Cas9, CRISPR-Cas12 and CRISPR-Cas13, in the development of fast, accurate and portable diagnostic tests and highlight the potential of CRISPR-Cas13 in COVID-19 Pneumonia and other emerging infectious diseases diagnosis.
新发传染病仍然是一种全球性威胁，持续存在引发大流行的潜在风险，导致过高的发病率和死亡率。目前由 2019 年新型冠状病毒（COVID-19）引起的肺炎疫情表明，缺乏有效的治疗药物是多么困难。准确、快速的诊断工具对于传染病的早期识别和治疗至关重要，这可以及时实施感染控制、改善临床护理和其他公共卫生措施，以阻止疾病的传播。CRISPR-Cas 技术通过快速、准确的方法加速了传染病诊断的发展。在这篇综述中，我们总结了目前在快速、准确和便携诊断测试开发方面不同的 CRISPR-Cas 系统的最新进展，包括 CRISPR-Cas9、CRISPR-Cas12 和 CRISPR-Cas13，并强调了 CRISPR-Cas13 在 COVID-19 肺炎和其他新发传染病诊断方面的潜力。
